J&J Ready To Capitalize On Zyrtec OTC Launch As Allergy Drug Hits Shelves
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's consumer product business is positioned to capitalize on the launch of nonprescription Zyrtec (cetirizine HCl) allergy medicine, J&J CEO Bill Weldon said during the firm's year-end analyst meeting Jan. 22
You may also be interested in...
J&J Expects Sales Loss To Be Skin-Deep, Looks To Skin-Care Lines For Boost
Johnson & Johnson looks to rebound from its first yearly decline in sales since the Depression in part by capitalizing on momentum in its skin-care business with extensions of its Aveeno, Neutrogena and RoC lines designed to meet anti-aging needs around the clock
J&J Expects Sales Loss To Be Skin-Deep, Looks To Skin-Care Lines For Boost
Johnson & Johnson looks to rebound from its first yearly decline in sales since the Depression in part by capitalizing on momentum in its skin-care business with extensions of its Aveeno, Neutrogena and RoC lines designed to meet anti-aging needs around the clock
J&J Expects Sales Loss To Be Skin-Deep, Looks To Skin-Care Lines For Boost
Johnson & Johnson looks to rebound from its first yearly decline in sales since the Depression in part by capitalizing on momentum in its skin-care business with extensions of its Aveeno, Neutrogena and RoC lines designed to meet anti-aging needs around the clock